IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New kidney drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug could reduce protein in the urine and protect kidney function compared to a placebo. The trial is now complete, and results will help determ…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Gut bacteria study hopes to ease kidney disease
Disease control CompletedThis study tested whether a probiotic supplement could change gut bacteria and reduce harmful antibodies in people with IgA nephropathy, a kidney disease. 18 adults took the probiotic for 3 months. Researchers measured changes in antibody levels and kidney function over 6 months …
Matched conditions: IGA NEPHROPATHY
Phase: NA • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New drug shows promise for rare kidney conditions
Disease control CompletedThis study tested an experimental drug called ARO-C3 in 62 healthy adults and patients with kidney diseases caused by an overactive immune system (C3 glomerulopathy and IgA nephropathy). The goal was to see if the drug is safe and how the body processes it. Participants received …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New pill shows promise in slowing rare kidney disease
Disease control CompletedThis study tested a drug called iptacopan (LNP023) in 518 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants took either the drug or a placebo alongside their usual care. The goal was to see if iptacopan could reduce protein in the urine a…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New IgA nephropathy drug shows early promise in small trial
Disease control CompletedThis study tested a new drug called XH-S003 in 25 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage, after 90 days. Participants had to have a kidney biopsy confirming the disease. T…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: S-INFINITY Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug combo shows promise for kidney disease in small trial
Disease control CompletedThis study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasenta…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New kidney drug shows early promise in small trial
Disease control CompletedThis early-stage study tested a new drug called ARO-CFB in 49 healthy volunteers and people with a kidney disease called IgA nephropathy. The main goal was to check if the drug is safe and how the body processes it. Participants received either one or two doses of the drug or a p…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New hope for kidney disease: early combo therapy may slow IgA nephropathy
Disease control CompletedThis study tested whether adding early steroids or SGLT2 inhibitors to standard blood pressure medication can better protect kidney function in people with IgA nephropathy who have severe kidney damage. 62 adults with active disease were randomly assigned to receive either the co…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 01, 2026 18:05 UTC
-
Brain-Gut-Kidney link may explain memory loss in kidney disease patients
Knowledge-focused CompletedThis study looked at why people with IgA nephropathy (a kidney disease) often have trouble with memory and thinking. Researchers used advanced brain scans and analyzed gut bacteria and blood samples from 100 patients and 100 healthy people. The goal was to find connections betwee…
Matched conditions: IGA NEPHROPATHY
Sponsor: Tang-Du Hospital • Aim: Knowledge-focused
Last updated Jun 16, 2026 22:19 UTC
-
First human test of kidney disease drug shows promise
Knowledge-focused CompletedThis early-stage study tested a new drug called VIS649 in 51 healthy adults to see if it is safe and how the body processes it. The drug aims to treat IgA nephropathy, a kidney disease. Participants received either the drug or a placebo, and researchers monitored side effects and…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:48 UTC